Format

Send to

Choose Destination
Nat Rev Drug Discov. 2016 Jan;15(1):51-69. doi: 10.1038/nrd.2015.9. Epub 2015 Nov 16.

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Author information

1
Clinica Medica "Cesare Frugoni", Dipartimento Interdisciplinare di Medicina, UniversitĂ  degli studi di Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy.
2
Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori "Giovanni Paolo II", Viale O. Flacco 65, 70124 Bari, Italy.
3
Letscom srl, via T. Bell 5, 00015 Monterotondo (RM), Italy.

Abstract

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

PMID:
26567701
DOI:
10.1038/nrd.2015.9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center